Background: Treatment of in-stent restenosis (ISR) has emerged as an important clinical entity. Drug-eluting balloon (DEB) has been considered as a alternative for treatment of ISR. We examined clinical outcomes of Paclitaxel-eluting balloon (PEB) in patients with ISR, retrospectively. Methods: From December 2009 to November 2010, 38 patients (40 lesions) with ISR who were treated with paclitaxel-eluting balloon (3µg/mm짼 of balloon surface area; SeQuent��� please) were analyzed retrospectively. Result: We examined the result of treatment with PEB for 38 patients, at 12 months. A mean age of patients were 61.6짹10.1 years and 50% of them were men. The prevalence of diabetes and chronic renal disease (Creatinine ���1.5mg/dl) were 43% and 3% respectively. Clinical diagnosis were stable angina (45%), unstable angina (35%) and non ST elevation MI (3%). Angiographically, one vessel disease was 58% and LAD is the major affected vessel (70%). The pattern of ISR were IA (2.5%), IB (25%) ,IC (35%), ID (2.5%), II (25%), III (10%) and IV (2.5%). A mean of lesion length and reference diameter were 16.4짹12.5mm and 2.97짹0.42mm respectively. A mean of diameter and length of PEB were 2.88 짹 0.35 mm and 19.8 짹 5.6 mm, respectively. The complications were 3 cases of coronary dissection. Major adverse cardiac events (MACE) were 1 death at 6 month and 1 target lesion revascularization (TLR) at 12 month. Conclusion: Treatment of coronary ISR with PEB was efficient and safe during 12 months follow-up period.